In several abstracts presented at this year's American Academy of Neurology Annual Meeting, Mitzi Joi Williams, MD, FAAN, Joi Life Wellness Neurology Clinic, explores multiple sclerosis–related outcomes in diverse patient populations.
Mitzi Joi Williams, MD, FAAN, medical director and CEO, Joi Life Wellness Neurology Clinic, is an author on several abstracts being presented at this year’s American Academy of Neurology (AAN) Annual Meeting that explore outcomes from multiple sclerosis (MS) in diverse patient populations that include pregnant women and Black and Hispanic/Latinx individuals.
In this interview, she discusses the findings of “An Interim Analysis of Efficacy and Safety Data in Black and Hispanic Patients With Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial.”
Transcript
What is the mechanism of action of ocrelizumab in relapsing MS?
Ocrelizumab is a B-cell–depleting agent. Essentially, by depleting B cells, we decrease the inflammatory response in the immune system, which results in many of the symptoms we see related to multiple sclerosis.
What are the principal findings of the CHIMES trial interim analysis that was presented at the AAN annual meeting?
The CHIMES trial was really birthed out of the need for information about MS [multiple sclerosis] in diverse populations. There is a lot of data, over the past decades, suggesting that the risk and incidence of MS is much higher in Black and Hispanic/Latinx communities than previously thought. However, when we look at our clinical trial data, there is very little enrollment of these populations in our phase 3 clinical research programs. Also, there are some studies that suggest that there may be differences in B-cell repletion in, for instance, African American communities and that that mechanism of action may be one that potentially could be very effective in those populations. So the scientific question, as well as the need for representation of these populations, is really what spurred the creation of the CHIMES trial.
In terms of the interim analysis, we're very excited to report out the data about NIDA [National Institute on Drug Abuse], which was very promising for the African American and Hispanic populations. Although the trial did not have a direct comparison to White populations, the trial design was very similar to some of the other programs, such as the OBOE study, and so we plan to hopefully compare some of that data to determine if the minority populations did equally as well as the White populations in some of the other bigger phase 3 programs.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More